



Press Release

At Oxford Immunotec:

Dr Peter Wrighton-Smith, CEO
Tel: +44 (0)1235 442780
Fax: +44 (0)1235 442781
Email: info@oxfordimmunotec.com

Oxford Immunotec
94C Milton Park
Abingdon
Oxfordshire OX14 4RY, UK

Report highlights the reliability of T-SPOT[®].TB following administration of the Tuberculin Skin Test.

Oxford, UK; 10th August 2007 – Oxford Immunotec Ltd, the T cell measurement company, today announced the report of a recent study demonstrating the reliability of T-SPOT.TB further confirming that it is not affected by a prior Tuberculin skin test.

In this study taken from the European Respiratory Journal T-SPOT.TB was not affected by the TST and was repeatedly negative. The result of the QuantiFERON-TB Gold In Tube test change from negative to positive in one third of these subjects.

Commenting on these results, Dr. Peter Wrighton-Smith, Chief Executive Officer of Oxford Immunotec said, “this report highlights the robustness of the T-SPOT.TB test compared to other tests used to identify TB infection. It confirms the results of earlier studies which have shown consistently that the T-SPOT.TB test alone is not affected by prior TST. This is an important feature of our test, especially as a number of TB control guidelines now recommend carrying out a TST followed by an interferon gamma test in those that are positive. This study indicates that only the T-SPOT.TB test will be unaffected by the earlier TST”.

- ENDS -

Notes to editors:

About Oxford Immunotec

www.oxfordimmunotec.com

Oxford Immunotec, the T cell measurement company, is headquartered near Oxford, UK. The Company develops and sells clinical diagnostic products based on its patented T-SPOT[®] technology, the first regulatory approved method for directly quantifying antigen-specific T cells.

T-SPOT is a simple and extremely accurate method of studying a person’s cellular immune response to infection and can be applied to diagnose and monitor any major disease driven by a T cell response.

About T-SPOT[®].TB

T-SPOT.TB is an *in vitro* T cell measurement assay used for diagnosing TB disease and latent TB infection and the first product from Oxford Immunotec using the T-SPOT technology. The product is extremely robust in that it gives a result every time and offers unrivalled and maintained sensitivity in high risk and immunocompromised patient groups. T-SPOT.TB is approved for sale in Europe, Canada & over 40 other countries worldwide and is

designed to replace the 115 year old Tuberculin Skin Test. As such it offers a substantially more accurate and effective tool for controlling the spread of TB, addressing a market exceeding \$1bn.

Unlike the traditional Tuberculin Skin Test, the T-SPOT. *TB* test incorporates a positive control, allowing the user to distinguish between a genuine negative result and one which is indeterminate (i.e. an inconclusive result) as a result of a technical failure.

T-SPOT is a trademark of Oxford Immunotec.

Journal Reference

Naseer A, Naqvi S and Kampmann B. Evidence for boosting Mycobacterium tuberculosis- specific IFN- γ responses at 6 weeks following tuberculin skin testing.

ERJ 2007; 29-6 pp 1282-1283